FDA Proposes Permanent End to GLP-1 Compounding

May 1, 2026 — The U.S. Food and Drug Administration announced on April 30 that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, effectively shutting down large-scale outsourcing facility compounding of these three blockbuster GLP-1 receptor agonist drugs. The proposal, published in the Federal Register on May 1, 2026, found no clinical need for outsourcing facilities to compound these drugs from bulk substances.

The Regulatory Framework

Under Section 503B of the Federal Food, Drug, and Cosmetic Act, outsourcing facilities may not compound drugs that are essentially copies of FDA-approved products unless the substance appears on the 503B bulks list or the drug appears on the FDA drug shortage list. During the 2022-2024 GLP-1 shortage, semaglutide's inclusion on the shortage list allowed 503B facilities to legally compound these drugs from bulk ingredients, creating an estimated $3-5 billion annual compounding market.

With the shortage resolved, the FDA's proposal removes both pathways — the bulks list exclusion and the shortage list — effectively creating a regulatory double-lock on mass compounding.

Impact on the Compounding Market

The proposed rule would affect hundreds of 503B outsourcing facilities across the United States that invested heavily in GLP-1 compounding. Key impacts include:

• Immediate demand reduction: 503B facilities will lose their primary revenue source from GLP-1 compounding once finalized
• Inventory write-downs: Compounding pharmacies holding bulk semaglutide, tirzepatide, or liraglutide face potential losses
• Transition challenges: Shifting to patient-specific compounding under Section 503A cannot support mass-compounding volume

API Demand Shift: From Compounding to Branded Supply

For API and intermediate suppliers, the FDA proposal creates a fundamental demand shift. The compounding channel has been a significant consumer of bulk semaglutide and tirzepatide API. With this channel closing:

• Consolidation toward branded manufacturers: Novo Nordisk and Eli Lilly will capture a larger share of total GLP-1 consumption, benefiting their API suppliers and contract manufacturers
• Authorized generic opportunities: Closure of the compounding channel may accelerate authorized generic programs, creating new API demand pathways
• Small molecule GLP-1 preparation: Oral GLP-1s like Eli Lilly's Foundayo (orforglipron), approved in April 2026, create demand for small molecule API expertise rather than peptide manufacturing

Strategic Implications for B2B Suppliers

API suppliers should consider several strategic responses:

• Capacity reallocation: Pivot compounding-channel capacity toward branded API supply, authorized generics, or emerging GLP-1 molecules
• Portfolio diversification: Over-reliance on compounding revenue creates regulatory vulnerability
• Regulatory monitoring: The FDA comment period runs through June 29, 2026 — suppliers should track developments closely

Public comments on the proposed rule are due by June 29, 2026. The FDA will consider these before issuing a final determination, expected by late 2026.